Acute Kidney InjuryNCT07765030
Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Receiving Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department
An observational study of Acute Kidney Injury and Kidney Failure, Acute, run by Antalya Health Sciences University at 1 site in Turkey (Türkiye).
Trial summary
This retrospective observational study aims to evaluate the clinical characteristics and in-hospital outcomes of critically ill adult patients who underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Kidney Injury, Kidney Failure, Acute, Kidney Failure
- What is being tested?
- Hemodialysis (HD) and Continuous Venovenous Hemodiafiltration (CVVHDF)
- Type of treatment
- Surgery or procedure
- How many people
- 150 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 10 Aug 2026to 1 Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population will consist of critically ill adult patients aged 18 years or older who were managed in the critical care area of the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026, and who underwent emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF). All eligible patients meeting the predefined inclusion and exclusion criteria during the study period will be included using a census sampling approach. Data will be obtained retrospectively from the hospital information management system, electronic medical records, laboratory records, renal replacement therapy records, and clinical follow-up notes. No direct participant recruitment or contact will occur.
Who may be able to join
- Age 18 years or older.
- Followed in the critical care area of the Emergency Department of Antalya
- Training and Research Hospital between January 1, 2023, and August 1, 2026.
- Presence of an indication for emergency renal replacement therapy.
- Underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the emergency department.
- Required critical care-level monitoring or management.
- Availability of sufficient demographic, clinical, laboratory, and in-hospital outcome data in the hospital information system, electronic medical records, laboratory records, or clinical follow-up notes.
Who cannot join
- Age younger than 18 years.
- Renal replacement therapy initiated outside the emergency department.
- Presentation only for routine chronic hemodialysis at the hospital dialysis unit without receiving renal replacement therapy in the emergency department.
- Renal replacement therapy planned in the emergency department but HD or CVVHDF could not be performed.
- Missing essential clinical, laboratory, or in-hospital outcome data. In patients with repeated emergency department admissions, only the first emergency renal replacement therapy episode will be included to reduce statistical dependency.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
University of Health Sciences, Antalya Training and Research Hospital
Antalya, konyaaltı, 21090
murat Duyan, ASSOCIATE PROFESSOR, +90 540 412 0735, drmuratduyan@gmail.com
abdurrahman cilingir, Postdoctoral research assistan
About this study
Official title: Evaluation of Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Undergoing Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department
This retrospective observational study aims to evaluate the clinical characteristics and in-hospital outcomes of critically ill adult patients who underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026.
Medical records will be reviewed to collect information on patient demographics, comorbidities, clinical findings at admission, vital signs, renal replacement therapy indications, laboratory results before and after treatment, treatment modality, treatment-related complications, need for intubation or vasopressor/inotropic support, intensive care unit admission, length of stay, and hospital outcomes.
The primary outcome is in-hospital mortality. Secondary outcomes include emergency department mortality, intensive care unit admission, ward admission, discharge status, emergency department and hospital length of stay, need for intubation or vasopressor/inotropic support, treatment completion, treatment-related complications, and changes in laboratory parameters before and after renal replacement therapy. No additional intervention, test, treatment, or biological sample collection will be performed as part of this study.
Read the detailed description
Emergency renal replacement therapy may be required in critically ill patients with life-threatening conditions such as severe hyperkalemia, refractory metabolic acidosis, fluid overload or pulmonary edema, uremic complications, acute kidney injury, acute deterioration in patients with chronic kidney disease, sepsis-associated renal dysfunction, cardiorenal syndrome, or selected intoxications. In routine clinical practice, these patients are generally managed in intensive care settings. However, when intensive care capacity is limited or transfer to the hospital dialysis unit is not clinically feasible, renal replacement therapy may need to be initiated and continued in an emergency department critical care area.
This single-center, retrospective, observational, descriptive-analytical study will review the medical records of critically ill adult patients who received hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026. Data will be obtained from the hospital information management system, electronic medical records, laboratory records, clinical follow-up notes, renal replacement therapy records, and discharge summaries.
The study will characterize the clinical profile of patients requiring emergency renal replacement therapy and examine treatment indications, treatment modality, treatment course, pre- and post-treatment laboratory findings, treatment-related complications, and in-hospital clinical outcomes. Renal replacement therapy indications will be evaluated under predefined clinical categories, and patients with more than one indication may be classified in more than one category. Laboratory changes, particularly in potassium, pH, bicarbonate, urea, creatinine, and lactate, will be assessed using available routine clinical measurements before and after treatment.
The study is intended to provide descriptive and exploratory evidence regarding the use of HD and CVVHDF in critically ill patients managed in the emergency department and to contribute to the evaluation of emergency critical care processes in settings where intensive care capacity may be limited. No study-specific intervention will be performed, and all analyses will be based exclusively on routinely collected retrospective clinical data.
- Conditions
- Acute Kidney Injury, Kidney Failure, Acute, Kidney Failure
- Being tested
- Hemodialysis (HD), Continuous Venovenous Hemodiafiltration (CVVHDF)
- Keywords
- Emergency Renal Replacement Therapy, Hemodialysis, Continuous Venovenous Hemodiafiltration, Acute Kidney Injury, In-Hospital Mortality
- Medical subject headings
- Acute Kidney Injury, Renal Insufficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hemodialysis (HD)Procedure or surgery
Hemodialysis performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy.
Continuous Venovenous Hemodiafiltration (CVVHDF)Procedure or surgery
Continuous venovenous hemodiafiltration performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy.
| Study group | Role | What they receive |
|---|---|---|
| Hemodialysis (HD) Group | Critically ill adult patients who underwent hemodialysis (HD) in the emergency department for an emergency renal replacement therapy indication during the study period. Receives: Procedure: Hemodialysis (HD); Procedure: Continuous Venovenous Hemodiafiltration (CVVHDF) | |
| Continuous Venovenous Hemodiafiltration (CVVHDF) Group | Critically ill adult patients who underwent continuous venovenous hemodiafiltration (CVVHDF) in the emergency department for an emergency renal replacement therapy indication during the study period. Receives: Procedure: Hemodialysis (HD); Procedure: Continuous Venovenous Hemodiafiltration (CVVHDF) |
What is being measured
The primary outcome is the main question the study is designed to answer.
In-Hospital Mortality
Number and proportion of patients who die during the index hospitalization following emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF).
Measured: Up to 30 days from emergency department admission
Secondary outcomes (3)
Emergency Department Mortality
Number and proportion of patients who die during their emergency department stay.
Measured: Up to 1 day from emergency department admission
Intensive Care Unit Admission
Number and proportion of patients requiring admission to an intensive care unit following emergency renal replacement therapy.
Measured: Up to 1 day from emergency department admission
Renal Replacement Therapy-Related Complications
Number and proportion of patients experiencing complications during renal replacement therapy, including hypotension, arrhythmia, cardiac arrest, bleeding, catheter-related problems, or device/technical problems.
Measured: Up to 8 hours from emergency department admission
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2026
- Study start10 Aug 2026 (estimated)
- Primary completion1 Nov 2026 (estimated)
- Study completion1 Nov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 150 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Antalya Health Sciences University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07765030
- Sponsor's protocol ID
- 13/45
- Status last verified
- Aug 2026
- First submitted
- 7 Aug 2026
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared because the study is based on retrospective clinical records containing sensitive patient information. Only anonymized, aggregated study results will be reported.
Publications
Kim JE, Jeong J, Choi Y, Moon HJ. Utilization of Renal Replacement Therapy and Its Impact on the Emergency Department Length of Stay in South Korean Emergency Medical Centers. Medicina (Kaunas). 2026 Jul 1;62(7):1273. doi: 10.3390/medicina62071273.
PubMed 42512815Meersch-Dini M, Abu-Tair M, Bayer M, Brinkmann A, Bellmann R, Brunkhorst F, Custodis F, Czock D, Frey O, Galle J, Hermes C, Joannidis M, John S, Jorres A, Kerz T, Kindgen-Milles D, Koczor M, Kram R, Kuhlmann M, Oppert M, Schlieper G, Schmitz M, Zarbock A, Willam C. Multidisciplinary guidelines on renal replacement therapy in intensive care medicine. Crit Care. 2026 Jan 14;30(1):46. doi: 10.1186/s13054-025-05817-6.
PubMed 41535952
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Clinical Characteristics and In-Hospital Outcomes of Critically Ill Patients Undergoing Hemodialysis or Continuous Venovenous Hemodiafiltration in the Emergency Department
- ClinicalTrials.gov ID
- NCT07765030
- Acronym / sponsor ID
- 13/45
- Conditions
- Acute Kidney Injury, Kidney Failure, Acute, Kidney Failure
- Keywords
- Emergency Renal Replacement Therapy, Hemodialysis, Continuous Venovenous Hemodiafiltration, Acute Kidney Injury, In-Hospital Mortality
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 150 participants (estimated)
- Lead sponsor
- Antalya Health Sciences UniversityUniversity, hospital or other
- Study start
- 10 Aug 2026 (estimated)
- Primary completion
- 1 Nov 2026 (estimated)
- Study completion
- 1 Nov 2026 (estimated)
- First posted
- 14 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective observational study aims to evaluate the clinical characteristics and in-hospital outcomes of critically ill adult patients who underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026.
Medical records will be reviewed to collect information on patient demographics, comorbidities, clinical findings at admission, vital signs, renal replacement therapy indications, laboratory results before and after treatment, treatment modality, treatment-related complications, need for intubation or vasopressor/inotropic support, intensive care unit admission, length of stay, and hospital outcomes.
The primary outcome is in-hospital mortality. Secondary outcomes include emergency department mortality, intensive care unit admission, ward admission, discharge status, emergency department and hospital length of stay, need for intubation or vasopressor/inotropic support, treatment completion, treatment-related complications, and changes in laboratory parameters before and after renal replacement therapy. No additional intervention, test, treatment, or biological sample collection will be performed as part of this study.
Detailed description
Emergency renal replacement therapy may be required in critically ill patients with life-threatening conditions such as severe hyperkalemia, refractory metabolic acidosis, fluid overload or pulmonary edema, uremic complications, acute kidney injury, acute deterioration in patients with chronic kidney disease, sepsis-associated renal dysfunction, cardiorenal syndrome, or selected intoxications. In routine clinical practice, these patients are generally managed in intensive care settings. However, when intensive care capacity is limited or transfer to the hospital dialysis unit is not clinically feasible, renal replacement therapy may need to be initiated and continued in an emergency department critical care area.
This single-center, retrospective, observational, descriptive-analytical study will review the medical records of critically ill adult patients who received hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026. Data will be obtained from the hospital information management system, electronic medical records, laboratory records, clinical follow-up notes, renal replacement therapy records, and discharge summaries.
The study will characterize the clinical profile of patients requiring emergency renal replacement therapy and examine treatment indications, treatment modality, treatment course, pre- and post-treatment laboratory findings, treatment-related complications, and in-hospital clinical outcomes. Renal replacement therapy indications will be evaluated under predefined clinical categories, and patients with more than one indication may be classified in more than one category. Laboratory changes, particularly in potassium, pH, bicarbonate, urea, creatinine, and lactate, will be assessed using available routine clinical measurements before and after treatment.
The study is intended to provide descriptive and exploratory evidence regarding the use of HD and CVVHDF in critically ill patients managed in the emergency department and to contribute to the evaluation of emergency critical care processes in settings where intensive care capacity may be limited. No study-specific intervention will be performed, and all analyses will be based exclusively on routinely collected retrospective clinical data.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Hemodialysis (HD) Group | – | Procedure: Hemodialysis (HD), Procedure: Continuous Venovenous Hemodiafiltration (CVVHDF)Critically ill adult patients who underwent hemodialysis (HD) in the emergency department for an emergency renal replacement therapy indication during the study period. |
| Continuous Venovenous Hemodiafiltration (CVVHDF) Group | – | Procedure: Hemodialysis (HD), Procedure: Continuous Venovenous Hemodiafiltration (CVVHDF)Critically ill adult patients who underwent continuous venovenous hemodiafiltration (CVVHDF) in the emergency department for an emergency renal replacement therapy indication during the study period. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of critically ill adult patients aged 18 years or older who were managed in the critical care area of the Emergency Department of Antalya Training and Research Hospital between January 1, 2023, and August 1, 2026, and who underwent emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF). All eligible patients meeting the predefined inclusion and exclusion criteria during the study period will be included using a census sampling approach. Data will be obtained retrospectively from the hospital information management system, electronic medical records, laboratory records, renal replacement therapy records, and clinical follow-up notes. No direct participant recruitment or contact will occur.
Key inclusion criteria (7 listed)
- Age 18 years or older.
- Followed in the critical care area of the Emergency Department of Antalya
- Training and Research Hospital between January 1, 2023, and August 1, 2026.
- Presence of an indication for emergency renal replacement therapy.
- Underwent hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF) in the emergency department.
Key exclusion criteria (5 listed)
- Age younger than 18 years.
- Renal replacement therapy initiated outside the emergency department.
- Presentation only for routine chronic hemodialysis at the hospital dialysis unit without receiving renal replacement therapy in the emergency department.
- Renal replacement therapy planned in the emergency department but HD or CVVHDF could not be performed.
- Missing essential clinical, laboratory, or in-hospital outcome data. In patients with repeated emergency department admissions, only the first emergency renal replacement therapy episode will be included to reduce statistical dependency.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hemodialysis (HD)Hemodialysis performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy. | Procedure or surgery | Continuous Venovenous Hemodiafiltration (CVVHDF) Group, Hemodialysis (HD) Group |
| Continuous Venovenous Hemodiafiltration (CVVHDF)Continuous venovenous hemodiafiltration performed in the emergency department as part of routine clinical care in critically ill adult patients with an indication for emergency renal replacement therapy. | Procedure or surgery | Continuous Venovenous Hemodiafiltration (CVVHDF) Group, Hemodialysis (HD) Group |
Primary outcome
In-Hospital Mortality
Time frame: Up to 30 days from emergency department admission
Number and proportion of patients who die during the index hospitalization following emergency renal replacement therapy with hemodialysis (HD) or continuous venovenous hemodiafiltration (CVVHDF).
3 secondary outcomes
Emergency Department Mortality
Time frame: Up to 1 day from emergency department admission
Intensive Care Unit Admission
Time frame: Up to 1 day from emergency department admission
Renal Replacement Therapy-Related Complications
Time frame: Up to 8 hours from emergency department admission
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Background: PubMed 42512815Kim JE, Jeong J, Choi Y, Moon HJ. Utilization of Renal Replacement Therapy and Its Impact on the Emergency Department Length of Stay in South Korean Emergency Medical Centers. Medicina (Kaunas). 2026 Jul 1;62(7):1273. doi: 10.3390/medicina62071273.
- Background: PubMed 41535952Meersch-Dini M, Abu-Tair M, Bayer M, Brinkmann A, Bellmann R, Brunkhorst F, Custodis F, Czock D, Frey O, Galle J, Hermes C, Joannidis M, John S, Jorres A, Kerz T, Kindgen-Milles D, Koczor M, Kram R, Kuhlmann M, Oppert M, Schlieper G, Schmitz M, Zarbock A, Willam C. Multidisciplinary guidelines on renal replacement therapy in intensive care medicine. Crit Care. 2026 Jan 14;30(1):46. doi: 10.1186/s13054-025-05817-6.
- Individual participant dataSharing planned: No. Individual participant data will not be shared because the study is based on retrospective clinical records containing sensitive patient information. Only anonymized, aggregated study results will be reported.
Related trials for Acute Kidney Injury
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Early Biomarker Kidney Injury Assessment After Acumen Directed Fluid Management in Cardiac Surgery
Renal Injury, Acute Kidney Injury
Recruiting
Acute Kidney Injury and Ultra-endurance Running
AKI (Acute Kidney Injury) Due to Trauma
Recruiting
WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Acute Hypoxic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
Not yet recruitingObservational study
Diastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy
Acute Kidney Injury, Hypotension (MeSH: D007022)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Kidney Injury and Kidney Failure, Acute, run by Antalya Health Sciences University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact murat Duyan, ASSOCIATE PROFESSOR (+90 540 412 0735, drmuratduyan@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
In-Hospital Mortality (time frame: Up to 30 days from emergency department admission). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07765030, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.